DNA Vaccines and Their Using in Veterinary Medicine

Öz

Veterinary area protects health of pet animals, farm animals and wild animals. Besides, it has many responsibilities about economical livestock management because of the infections in management, region, country or even large geographical area and human health because of the zoonotic infection. The formation of immune populations against several etiological agents correspondingly, the development of conventional vaccines or a portion of the etiological agent (nucleic acid or protein) containing vaccines (subunit vaccines, vector vaccines, DNA vaccines, etc.) are important issues in science. The purpose of this review is to provide general information about the DNA vaccines that are formed by expression plasmid vectors, which contain encoding genes of antigenic proteins of microorganism and draw attention to the use of veterinary facilities

Anahtar Kelimeler

• Vaccine, DNA Plasmid, Immunity

DNA Aşıları ve Veteriner Hekimlik Alanında Kullanımı

Öz

Veteriner hekimlik alanı pet hayvanları, çiftlik hayvanları, vahşi yaşamdaki hayvanların sağlığının korunmasının yanı sıra, işletme, bölge ya da ülkedeki ve hatta pandemik enfeksiyonlar nedeniyle geniş coğrafyalardaki çiftlik hayvanlarının ekonomik yetiştiriciliği, zoonoz enfeksiyonlar nedeniyle de, insan sağlığına ilgili sorumlulukları içermektedir. Bu bağlamda, birçok etken için bağışık popülasyonların oluşturulması; dolayısıyla geleneksel aşılar ya da etiyolojik ajanın bir kısmını (nükleik asit ya da protein) içeren aşıların (subunit aşı, vektör aşı, DNA aşısı, vb.) geliştirilmesi bilimin önemli konularındandır. Bu derlemenin amacı, mikroorganizmaların çeşitli antijenik karakterdeki proteinlerini kodlayan genlerin yerleştirildiği ekspresyon plazmid vektörleri olan DNA aşılarına ilgili genel bilgileri sunmak ve veteriner hekimlikte kullanım olanaklarına dikkat çekmektir

Anahtar Kelimeler

• Aşı, DNA Plazmid, Bağışıklık

Kaynakça

1. Amanna IJ, Slifka MK (2014). Current trends in West Nile virus vaccine development. Expert Rev Vaccines, 13(5), 589-608.
2. Arda M, Sareyyüpoğlu B (2004). Aşılar Hazırlama Teknikleri Avantaj ve Dezavantajları, İnkansa Yayınları, İskitler/Ankara.
3. Babiuk S, Baca-Estrada ME, Foldvari M, et al. (2002). Electroporation improves the efficiacy of DNA vaccines in large animals. Vaccine, 20, (27-28), 3399-3408.
4. Bergman PJ, Mcknight J, Novosad A, et al. (2003). Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogenic human tyrosinase: a phase ı trial. Clin Cancer Rest 9, 12841290.
5. Cao A, Liu Y, Wang J, et al. (2015). Toxoplasma gondii: Vaccination with a DNA vaccine encoding T- and B-cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice. Vaccine Pii, S0264-410X(15)01506-6.
6. Cicin-Sain L, Brune W, Bubic I, Jonjic S, Koszinowski UH (2003). Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo. J Virol, 77, 8249–8255
7. Davis BS, Chang GJ, Cropp B, et al. (2001). West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol, 75(9), 40404047.
8. De Azevedo M, Meijerink M, Taverne N, et al. (2015). Recombinant invasive Lactococcus lactis can transfer DNA vaccines either directly to dendritic cells or across an epithelial cell monolayer. Vaccine, 33(38), 4807-4812.

9. Dufour V, (2001). DNA vaccines: new applications for veterinary medicine. Vet Sci Tomorrow, 2, 1-26.
10. Dunham SP, Flynn JN, Rigby MA, et al. (2002). Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18. Vaccine, 20, 1483–1496.
11. Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR (1999). Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol, 162(3), 1603-1610.
12. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santaro JC, Robinson HL (1993). DNA vaccines: protective immunization by parenteral, mucosal and gene gun inoculation. Proc Natl Acad Sci USA, 90 (24), 11478-11482.
13. Glenting J, Wessels S (2005). Ensuring safety of DNA vaccines. Microb Cell Fact, 4, 26.
14. Gould-Fogerite S, Kheiri MT, Zhang F, et al. (1998). Targeting immune response induction with cochleate and liposome-based vaccines. Adv Drug Deliv Rev, 32(3), 273-287.
15. Gregoriadis G, Saffie R, de Souza JB (1997). Liposome-mediated DNA vaccination. FEBS lett, 402(2), 107-110.
16. Grunathan S, Klinman DM, Seder RA (2000). DNA vaccines immunology application and optimization. Annu Rev Immunol, 18, 927-974.
17. Gupta S, Leutenegger CM, Dean GA, Steckbeck JD, Cole KS, Sparger EE (2007). Vaccination with attenuated feline immunodeficiency virus proviral DNA vaccine expressing interferon γ. J Virol, 81, 465–473.
18. Hahn UK, Aichler M, Boehm R, Beyer W (2006). Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine, 24(21), 4595-4597.
19. Hanlon L, Argyle D, Bain D, et al. (2001). Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J Virol, 75(18), 8424–8433.
20. Herrmann JE, Chen SC, Jones DH, et al. (1999). Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology, 259(1), 148153.
21. Kaashoek MJ, Moerman A, Madic J, et al. (1995). An inactivated vaccine based on a glycoprotein E-negative strain of bovine herpesvirus 1 induces protective immunity and allows serological differentiation. Vaccine, 13(4), 342–346.
22. Khan AS, Draghia-Akli R, Shypailo RJ, Ellis KI, Mersmann H, Fiorotto ML (2010). A comparison of the growth responses following intramuscular ghrh plasmid administration versus daily growth hormone injections in young pigs. Mol Ther, 18, 327-333.
23. Kilpatrick AM, Dupuis AP, Chang GJ, Kramer LD (2010). DNA vaccination of american robins (Turdus Migratorius) against west nile virus. Vector Borne Zoonoptic Dis, 10, 377-380.
24. Kumaragurubaran K, Kaliaperumal K (2013). DNA vaccine: the miniature miracle. Vet World, 6(4), 228-232.
25. Kutzler MA, Weiner DB (2008). DNA vaccines: ready for prime time? Nat Rev Genet, 9, 776-788.
26. Laddy DJ, Yan J, Kutzler M, et al. (2008). Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One, 3(6), e2517.
27. Ledwith BJ, Manam S, Troilo PJ, et al. (2000). Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology, 43(4-6), 258-272.
28. Liu MA (2011). DNA vaccines: an historical perspective and view to the future. Immunol Rev, 239(1), 62-84.
29. Lodmell DL, Ewalt LC, Parnell MJ, Rupprecht CE, Hanlon CA (2006). One-time intradermal DNA vaccination in ear pinnae one year prior to infection protects dogs against rabies virus. Vaccine, 24(4), 412–416
30. Lorenzen N, Lapatra S (2005). DNA vaccines for aquacultured fish. Rev Sci Tech, 24(1), 201-213,
31. Martin JE, Pierson TC, Hubka S, et al. (2007). A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infec Dis, 196(12), 1732-1740.
32. McDonnell MW, Askari FK (1999). The emerging role of DNA vaccines. MedGenMed, 1(3).
33. Miki K, Nagata T, Tanaka T, et al. (2004). Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51. Infect and Immun, 72, 2014-2021.
34. Nabel GC, Kaslow DC, Ulmer JB, Liu MA (2010). DNA Vaccines IN New Generation Vaccines: Levine MM, Dougan D, Good MF, Liu MA, Nabel G, Nataro JP, Rappuoli R. (Ed) 386-395 Forth Edition, Informa Healthcare Inc.
35. Niborski V, Li Y, Brennan F, et al. (2006). Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV. Vaccine 24(49–50), 7204–7213.
36. Nobiron I, Thompson I, Brownlie J, Collins ME (2003). DNA vaccination against bovine viral diarrhoea virus induces humoral and cellular responses in cattle with evidence for protection against viral challenge. Vaccine, 21(17–18), 2082–2092.
37. Pereira VB, Zurita-Turk M, Saraiva TDL, et al. (2014). DNA vaccines approach: from concepts to applications. World Journal of Vaccines, 4, 50-71.
38. Purcell MK, Nichols KM, Winton JR, et al. (2006). Comprehensive gene expression profiling following DNA vaccination of rainbow trout against infectious hematopoietic necrosis virus. Mol Immunol, 43(13), 2089-2106.
39. Redding L, Weiner DB (2009). DNA vaccines in veterinary use. Expert Rev Vaccines, 8, 1251–1276.
40. Rosati M, Valentin A, Jalah R, et al. (2008). Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine, 26(40), 5223-5229.
41. Saint-Victor DS, Omer SB (2013). Vaccine refusal and the endgame: walking the last mile first. Philos Trans Rl Soc Lond B Biol Sci, 368(1623), 20120148.
42. Salonius K, Simard N, Harland R, Ulmer JB (2007). The road to licensure of a DNA vaccine. Curr Opin Investig, Drugs, 8(8), 635.
43. Sasaki S, Sumino K, Hamajima K, et al. (1998). Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS- 21 saponin adjuvant via intramuscular and intranasal routes. J Virol, 72, 4931– 39.
44. Schalk JAC, Mooi FR, Berbers GAM, van Aerts LAGJM, Ovelgönne H, Kimman TG (2006). Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin, 2 (2), 45-53.
45. Schoen C, Stritzker J, Goebel W, Pilgrim S (2004). Bacteria as DNA vaccine carriers for genetic immunization. Int J Med Microbiol, 294, 319–335
46. Tesoro-Cruz E, Calderon-Rodriguez R, Hernandez-Gonzalez R, BlancoFavela F, Aguilar-Setien A (2008). Intradermal DNA vaccination in ear pinnae is an efficient route to protect cats against rabies virus. Vet Res, 39(2), 16.
47. Tuting T, Austyn J, Storkus WJ, Falo Jr. LD (2000). The Immunology of DNA Vaccines. In: DNA Vaccines Methods and Protocols. Lowrie DB, Whalen RG. (Ed) 35, Humana Press Inc. Totowa, NJ.
48. Uttenthal A, Parida S, Rasmussen TB, Paton DJ, Haas B, Dundon WG (2010). Strategies for differentiating infection in vaccinated animals (DIVA) for foot-and-mouth disease, classical swine fever and avian influenza. Expert Rev Vaccines, 9(1), 73-87.
49. Van Den Hurk SDL, Braun RP, Babıuk LA (2000). Veterinary DNA Vaccines. In: DNA Vaccines Methods and Protocols. Lowrie DB, Whalen RG. (Ed), 79, Humana Press Inc. Totowa, NJ.
50. Wahren B, Liu MA (2014). DNA vaccines: recent developments and the future. Vaccines, 2(4), 785-796.
51. Walther W, Stein U (2000). Viral vectors for gene transfer. Drugs, 60(2), 249-271
52. Wolff JA, Malone RW, Williams P, et al. (1990). Direct gene transfer into mouse muscle in vivo. Science, 247(4949), 1465-1468.
53. Wong HT, Cheng SC, Sin FW, Chan EW, Sheng ZT, Xie Y (2002). A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2. Vaccine, 20(21–22), 2641–2647.
54. Woo PCY, Wong L, Zheng B, Yuen, K. (2001). Unique immunogenicity of hepatitis b virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine, 19, 2945-2954.
55. Xie L, Yan M, Wang X, et al. (2015) Immunogenicity and efficacy in mice of an adenovirus-based bicistronic rotavirus vaccine expressing NSP4 and VP7. Virus Res, 2, 210, 298-307.
56. Yang K, Whalen BJ, Tirabassi RS, et al. (2008). A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection. J Immunol, 180(9), 61596167.